Amy Macintyre
Child & Adolescent Psychiatry · Bala Cynwyd, PANPI 1609035260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations.
Across 141 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$468
- AbbVie$330
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$264
- Lundbeck LLC$195
- Takeda Pharmaceuticals U.S.A., Inc.$123
- Supernus Pharmaceuticals, Inc.$123
- plus $747 from 17 others
What the payments were for
- Food & beverage$2,20298%
- Education$492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,251 in reported general payments places this provider in the 80th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.
See all child & adolescent psychiatry providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 24 | $11,431 |
| Methylphenidate ErMethylphenidate Hcl | 19 | $2,785 |
| Vilazodone Hcl | 17 | $1,356 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $759 |
| Lamotrigine | 19 | $735 |
| Bupropion XlBupropion Hcl | 17 | $546 |
| Clonazepam | 39 | $481 |
| Lorazepam | 27 | $355 |
| Gabapentin | 17 | $264 |
| Duloxetine Hcl | 15 | $209 |
| Lithium Carbonate ErLithium Carbonate | 12 | $208 |
| Oxcarbazepine | 21 | $196 |
| Escitalopram Oxalate | 15 | $179 |
| Mirtazapine | 11 | $76 |
| Zolpidem Tartrate | 25 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $123 | $11,43124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.
Other child & adolescent psychiatry in Bala Cynwyd
- Dennis BorczonErie$120K
- Suzanne LucotCranberry Township$72K
- Dan UdreaWexford$51K
- Robert WilsonErie$34K
- Craig FeasterState College$18K
- Thomas WindPhiladelphia$17K
- Laura AdangPhiladelphia$15K
- Christoph LamPhiladelphia$13K
- Raman BawejaHershey$11K
- Jeffrey HermannYork$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.